NCT02799082已完成3 期
A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 122
- 主要终点
- Total Patient Clearance Rate 12 Weeks After the Last Photodynamic Therapy (PDT)
研究概览
简要总结
The aim of the study was to evaluate the efficacy and safety of BF-200 ALA (Ameluz) used with photodynamic therapy (PDT) in patients suffering from actinic keratosis.
详细描述
The treatment comprised of one PDT session. If 12 weeks after PDT all lesions were cleared the patient entered the follow-up period. In case of remaining lesions or not completely cleared lesions the patient received a second PDT on the same day. The final assessment was performed 12 weeks after the last PDT and the patient moved to the follow-up phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects were willing and able to sign informed consent form.
- •Men and women aged between 18 and 85 years inclusive.
- •Subjects had a general good and stable health condition as confirmed by a physical examination and by medical history.
- •Subjects with clinically stable medical conditions including, but not limited to the following diseases were allowed to be included into the study, if the medication taken for the treatment of the disease did not match the criteria of the excluded or disallowed medications listed in points 7, 10, 11 and 12 of the exclusion criteria:
- •controlled hypertension
- •diabetes mellitus type II
- •hypercholesterolemia
- •osteoarthritis
- •Subjects accepted to abstain from sunbathing and the solarium during the study.
- •Subjects had at least 4 but not more than 8 clinically confirmed actinic keratosis (AK) target lesions of mild to moderate intensity within the face or bald scalp (excluding eyelids, lips and mucosa), i.e. AK grade I and II according to Olsen et. al.
- •To document and confirm the diagnosis of the investigators:
- •Photodocumentation of a representative lesion had to be evaluated and confirmed by an independent expert.
- •A pre-study biopsy had to be taken from a second representative AK lesion and was histopathologically evaluated by a dermato-pathological expert.
- •If the evaluation of the photo by the independent reviewer could not confirm the diagnosis of the investigator, then the biopsy result decided whether the subject was eligible for the study.
- •The AK lesions had to be discrete and quantifiable; the distance from one lesion to its neighbor lesion was greater than 1.0 cm
- •The diameter of each AK lesion was not less than 0.5 cm and not greater than 1.5 cm. The size of each baseline AK lesion was recorded by measuring the two largest perpendicular diameters. To describe irregular lesions (ellipsoidal) investigators measured the major and minor axis. Both axes had to be above the minimum of 0.5 cm and less than 1.5 cm.
- •The subjects were free of any significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment area that might cause difficulty with examination or final evaluation.
- •The subjects were willing to stop using moisturizers and any other topical treatments with anti-aging products, vitamin A, vitamin C, and/or vitamin E containing ointments and creams, and green tea preparations during the study within the treatment area. Sunscreens were allowed, but were not to be applied in the treatment area within approximately 24 hours before a clinical visit with lesion count.
- •Women of childbearing potential were only allowed to participate in this study, if they used a highly effective method of contraception and had a negative serum pregnancy test.
排除标准
- •Had known hypersensitivity to 5-aminolevulinic acid (ALA).
- •Were subjects under immunosuppressive therapy.
- •Suffered from porphyria.
- •Showed hypersensitivity to porphyrins.
- •Suffered from photodermatoses.
- •Had inherited or acquired coagulation defects.
- •Had received medication with hypericin or systemically acting drugs with phototoxic or photoallergic potential such as psoralens, tetracyclines, nalidixic acid, furosemide, amiodarone, phenothiazines, quinolones, fibrates, or phytotherapy with St. John's wort, arnica, or valerian or topically applied phototoxic substances like tar, pitch, psoralens or some dyes like thiazide, methylene blue, toluidine blue, eosine, Bengal rose, acridine within 8 weeks prior to treatment with study drug and photodynamic therapy (PDT).
- •Had evidence of clinically significant, unstable medical conditions such as
- •metastatic tumor or tumor with high probability of metastatic spread
- •cardiovascular (NYHA class III, IV)
- •immunosuppressive
- •hematological, hepatic, renal, neurological, endocrine
- •collagen-vascular
- •gastrointestinal
- •Had currently other malignant or benign tumors of the skin within the treatment area (e.g., malignant melanoma, basal cell carcinoma, invasive squamous cell carcinoma).
- •Used any topical treatment in the treatment area within 12 weeks before PDT treatment with BF-200 ALA; biopsy taken at the screening visit was allowed.
- •Used topical treatment with ALA or MAL (methyl-aminolevulinic acid hydrochloride) outside the treatment area during participation in the study.
- •Systemic treatments of one of the following within the designated period before
- •PDT with BF-200 ALA:
- •Interferon - 6 weeks
- •Immunomodulators or immunosuppressive therapies - 10 weeks
- •Cytotoxic drugs - 6 months
- •Investigational drugs - 8 weeks
- •Drugs known to have major organ toxicity - 8 weeks
- •Corticosteroids (oral or injectable) - 6 weeks
- •Inhaled corticosteroids (>1200 µg/day for beclomethasone, or >600 µg/day for fluticasone) - 4 weeks
- •Methyl-aminolevulinic acid hydrochloride or ALA - 12 weeks
- •Known allergy against polysorbate 80, caprylic/capric acid triglycerides, isopropyl alcohol, disodium phosphate dihydrate, sodium hydroxide, hydrochloric acid, propylene glycol; sodium benzoate.
- •Were known to be pregnant or lactating (currently or within the past 3 months).
- •Had any dermatological disease in the treatment area or surrounding area that could be exacerbated by treatment with topical ALA or caused difficulty with examination (e.g. psoriasis, eczema).
- •Showed cornu cutaneum like alterations of the skin in the face or on the bald scalp (target area).
- •Were currently or within the past 8 weeks participating in another clinical study.
- •Had active chemical dependency or alcoholism as assessed by the investigator.
- •Confirmed diagnosis of HIV.
研究组 & 干预措施
Vehicle
Placebo Comparator
Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
干预措施: Vehicle (Drug)
BF-200 ALA
Active Comparator
Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
干预措施: BF-200 ALA (Drug)
结局指标
主要结局
Total Patient Clearance Rate 12 Weeks After the Last Photodynamic Therapy (PDT)
时间窗: 12 weeks after the last PDT, up to 24 weeks
AK clearance rate, defined as the percentage of subjects with complete remission of all AK lesions in the target area(s) assessed 12 weeks after the last PDT (12 weeks after the 1st PDT or 12 weeks after the 2nd PDT in case of retreatment).
Total Patient Clearance Rate Treated With Narrow Spectrum Lamp 12 Weeks After the Last Photodynamic Therapy (PDT)
时间窗: 12 weeks after the last PDT, up to 24 weeks
AK clearance rate, defined as the percentage of subjects with complete remission of all AK lesions in the target area(s) assessed 12 weeks after the last PDT (12 weeks after the 1st PDT or 12 weeks after the 2nd PDT in case of retreatment). Analysis was for the subgroup: treated by narrow spectrum lamps only \[n=13 (vehicle), n= 28 (BF-200 ALA)\]
次要结局
- Percentage of AK Lesions Showing Complete Remission 12 Weeks After the Last PDT(12 weeks after the last PDT, up to 24 weeks)
- Percentage of AK Lesions Showing Complete Remission Treated With Narrow Spectrum Lamp 12 Weeks After the Last PDT(12 weeks after the last PDT, up to 24 weeks)
- Change in Total Lesion Size 12 Weeks After the Last PDT(12 weeks after the last PDT, up to 24 weeks)
- Overall Cosmetic Outcome 12 Weeks After the Last PDT(12 weeks after the last PDT, up to 24 weeks)
- Local Skin Reactions(during and after PDT [3h - 4 h])
- Subjects With Complete Clearance 12 Weeks After the First PDT(12 weeks after the first PDT)
- Change in Total Lesion Area 12 Weeks After the Last PDT (Treated Area Face)(12 weeks after the last PDT, up to 24 weeks)
- Discomfort During and After PDT(during and after PDT [3h - 4 h])
- Change in Total Lesion Area 12 Weeks After the Last PDT (Treated Area Scalp)(12 weeks after the last PDT, up to 24 weeks)
- Subjects With Partial Clearance 12 Weeks After the Last PDT(12 weeks after the last PDT, up to 24 weeks)
- Related Adverse Events /AEs)(up to 24 weeks after the 1st PDT)
研究者
相似试验
已完成
3 期
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)Actinic KeratosisNCT01966120Biofrontera Bioscience GmbH87
已完成
3 期
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic TherapyActinic KeratosisNCT02799069Biofrontera Bioscience GmbH571
已完成
3 期
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney DiseaseDyslipidemiaKidney DiseaseNCT00680017AstraZeneca280
已完成
3 期
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)Glabellar Frown LinesNCT03985982Croma-Pharma GmbH410
已完成
3 期
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study IGlabellar Frown LinesNCT02677298Croma-Pharma GmbH784